Novel series of tunable µOR modulators with enhanced brain penetration for the treatment of opioid use disorder, pain and neuropsychiatric indications

Alok Nerurkar, Thomas Nguyen, Sheldon Wang, Ulhas Bhatt, Kevin Li, Yihong Li, Pingyu Ding, Frederick J. Seidl, Martin Holan, John Lee, Tien Widjaja, Zhi Liang Wei, Corinne Sadlowski, David Sperandio, Lawrence R. McGee, Beth Youngblood, Neil Schwartz, Donald Gehlert, Julio C. Medina

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Structural optimization of a previously reported agonist of µOR, PZM21 is described resulting in the discovery of a novel series of amides with at least 4-folds enhanced CNS penetration in rat. Furthermore, these efforts yielded compounds with varying levels of efficacy on the receptor ranging from high efficacy agonists such as compound 20 to antagonists, such as 24. The correlation between in vitro activation of µOR and relative activity in models of analgesia for these compounds is discussed. The compelling results obtained in these studies demonstrate the potential utility of these newly discovered compounds in the treatment of pain and opioid use disorder.

Original languageEnglish
Article number129405
JournalBioorganic and Medicinal Chemistry Letters
Volume92
DOIs
StatePublished - 15 Aug 2023
Externally publishedYes

Keywords

  • Analgesia
  • CNS Penetration
  • Opioid Use Disorder
  • SAR
  • µ-Opioid Receptor

Fingerprint

Dive into the research topics of 'Novel series of tunable µOR modulators with enhanced brain penetration for the treatment of opioid use disorder, pain and neuropsychiatric indications'. Together they form a unique fingerprint.

Cite this